In support of the PC-specific immunotherapy approaches there are numerous data showing how PC patients generate B and T cells specific to antigens expressed on autologous pancreatic tumor cells [10–12], such as Wilms' tumor gene 1 (WT1) (75%) [13], mucin 1 (MUC1) (over 85%) [14], human telomerase reverse transcriptase (hTERT) (88%) [15], mutated K-RAS (73%) [16], survivin (77%) [17], carcinoembryonic antigen (CEA) (over 90%) [18], HER-2/neu (61.2%) [19], p53 (67%) [20], and α-enolase [21]. The gene discussed is KRAS; the disease is pancreatic neoplasm.